Comparison of tegoprazan and proton pump inhibitors for first-line Helicobacter pylori eradication: a systematic review with meta-analysis.

IF 4.2 2区医学 Q1 INFECTIOUS DISEASES

Expert Review of Anti-infective Therapy Pub Date : 2025-02-01 Epub Date: 2025-01-29 DOI:10.1080/14787210.2025.2459722

Jun-Hyung Cho, So-Young Jin, Suyeon Park

{"title":"Comparison of tegoprazan and proton pump inhibitors for first-line Helicobacter pylori eradication: a systematic review with meta-analysis.","authors":"Jun-Hyung Cho, So-Young Jin, Suyeon Park","doi":"10.1080/14787210.2025.2459722","DOIUrl":null,"url":null,"abstract":"Background: Tegoprazan (TPZ), a potassium-competitive acid blocker with potent gastric acid-suppressing activity, may be a potential agent for treating Helicobacter pylori infection. The study aimed to evaluate the efficacy of TPZ-based therapy for H. pylori eradication compared with proton pump inhibitor (PPI)-based therapy.Research design and methods: A comprehensive literature search was conducted up to August 2024 using PubMed, Embase, and the Cochrane Library to investigate the beneficial effects of TPZ-based therapy for H. pylori eradication. Studies that evaluated the eradication rates between the TPZ- and PPI-based therapies were included. The authors conducted a meta-analysis to calculate the eradication rate and pooled risk ratio (RR) with a 95% confidence interval.Results: Seven studies involving 3200 patients were included. H. pylori eradication rates did not differ significantly between the TPZ- and PPI-based therapies based on the intention-to-treat (77.3% vs. 76.4%, p = 0.68; pooled RR = 1.01 [0.97-1.05]) and per-protocol (84.3% vs. 84.2%, p = 0.69; pooled RR = 1.01 [0.98-1.04]) analyses. Additionally, no significant difference was observed in the adverse drug events between TPZ- and PPI-based therapies (27.2% vs. 30.8%, p = 0.26; pooled RR = 0.91 [0.76-1.08]).Conclusions: H. pylori eradication and adverse drug event rates with TPZ- and PPI-based treatments were similar.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"227-233"},"PeriodicalIF":4.2000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anti-infective Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14787210.2025.2459722","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/29 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Tegoprazan (TPZ), a potassium-competitive acid blocker with potent gastric acid-suppressing activity, may be a potential agent for treating Helicobacter pylori infection. The study aimed to evaluate the efficacy of TPZ-based therapy for H. pylori eradication compared with proton pump inhibitor (PPI)-based therapy.

Research design and methods: A comprehensive literature search was conducted up to August 2024 using PubMed, Embase, and the Cochrane Library to investigate the beneficial effects of TPZ-based therapy for H. pylori eradication. Studies that evaluated the eradication rates between the TPZ- and PPI-based therapies were included. The authors conducted a meta-analysis to calculate the eradication rate and pooled risk ratio (RR) with a 95% confidence interval.

Results: Seven studies involving 3200 patients were included. H. pylori eradication rates did not differ significantly between the TPZ- and PPI-based therapies based on the intention-to-treat (77.3% vs. 76.4%, p = 0.68; pooled RR = 1.01 [0.97-1.05]) and per-protocol (84.3% vs. 84.2%, p = 0.69; pooled RR = 1.01 [0.98-1.04]) analyses. Additionally, no significant difference was observed in the adverse drug events between TPZ- and PPI-based therapies (27.2% vs. 30.8%, p = 0.26; pooled RR = 0.91 [0.76-1.08]).

Conclusions: H. pylori eradication and adverse drug event rates with TPZ- and PPI-based treatments were similar.

查看原文本刊更多论文

替戈拉赞和质子泵抑制剂用于一线幽门螺杆菌根除的比较：一项荟萃分析的系统综述。

背景：替戈拉赞（TPZ）是一种具有强抑胃酸活性的钾竞争性酸阻滞剂，可能是治疗幽门螺杆菌感染的潜在药物。本研究旨在评价以tpz为基础的治疗与以质子泵抑制剂（PPI）为基础的治疗对幽门螺杆菌根除的疗效。研究设计和方法：利用PubMed、Embase和Cochrane Library检索截止到2024年8月的文献，探讨tpz为基础的治疗根除幽门螺杆菌的有益效果。评估基于TPZ和基于ppi的治疗之间根除率的研究被包括在内。作者进行了一项荟萃分析，以95%的置信区间计算根除率和合并风险比（RR）。结果：纳入7项研究，涉及3200例患者。基于意向治疗的TPZ和ppi疗法的幽门螺杆菌根除率无显著差异(77.3% vs. 76.4%, p = 0.68；汇集RR = 1.01(0.97 - -1.05))和按方案(84.3%比84.2%,p = 0.69;合并RR = 1.01[0.98-1.04])分析。此外，基于TPZ和基于ppi的治疗在药物不良事件方面没有显著差异(27.2% vs 30.8%, p = 0.26；pooled RR = 0.91[0.76-1.08])。结论：TPZ治疗和ppi治疗的幽门螺杆菌根除率和药物不良事件发生率相似。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Anti-infective Therapy 医学-药学

CiteScore

11.20

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anti-Infective Therapy (ISSN 1478-7210) provides expert reviews on therapeutics and diagnostics in the treatment of infectious disease. Coverage includes antibiotics, drug resistance, drug therapy, infectious disease medicine, antibacterial, antimicrobial, antifungal and antiviral approaches, and diagnostic tests.